CDKN1B V109G polymorphism frequency and prostate cancer risk in Taiwan

Urologia Internationalis

Volumn 81, Issue 1, 2008, Pages 36-40

  Huang, Shu Pin ^a,b   Yu, Chia Cheng ^c   Liu, Chia Chu ^a   Wu, Tony T ^c   Huang, Chun Hsiung ^a,b   Wu, Ming Tsang ^a,d  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

CDKN1B; Genetic polymorphism; Prostate cancer, Taiwan

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER STAGING; CONFIDENCE INTERVAL; DISEASE COURSE; DISEASE SEVERITY; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HORMONAL THERAPY; HORMONE RESPONSE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REAL TIME POLYMERASE CHAIN REACTION; RISK; STATISTICAL SIGNIFICANCE; TAIWAN; TERMINAL OLIGOPYRIMIDINE TRACT;

AGED; CASE-CONTROL STUDIES; CELL CYCLE; DISEASE PROGRESSION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSTATIC NEOPLASMS; RISK; TAIWAN; TUMOR MARKERS, BIOLOGICAL;

EID: 47949127171     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000137638     Document Type: Article

References (21)

1. Sherr CJ: Cancer cell cycles. Science 1996;274:1672-1677.
2. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of g1-phase progression. Genes Dev 1999;13:1501-1512.
3. Slingerland J, Pagano M: Regulation of the CDK inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000;183:10-17.
4. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW: p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999;154:313-323.
5. Macri E, Loda M: Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev 1998;17:337-344.
6. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP: Pten and p27kip1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 2001;27:222-224.
7. Cave H, Martin E, Devaux I, Grandchamp B: Identification of a polymorphism in the coding region of the p27kip1 gene. Ann Genet 1995;38:108.
8. Tomoda K, Kubota Y, Kato J: Degradation of the cyclin-dependent-kinase inhibitor p27kip1 is instigated by jab1. Nature 1999;398:160-165.
9. Kibel AS, Suarez BK, Belani J, Oh J, Webster R, Brophy-Ebbers M, Guo C, Catalona WJ, Picus J, Goodfellow PJ: CDKn1a and CDKn1b polymorphisms and risk of advanced prostate carcinoma. Cancer Res 2003;63:2033-2036.
10. Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Klotz LH, Slingerland JM: Loss of cyclin-dependent kinase inhibitor p27kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998;58:542-548.
11. Cote RJ, Shi Y, Groshen S, Feng AC, Cordon-Cardo C, Skinner D, Lieskovosky G: Association of p27kip1 levels with recurrence and survival in patients with stage c prostate carcinoma. J Natl Cancer Inst 1998;90:916-920.
12. Freedland SJ, deGregorio F, Sacoolidge JC, Elshimali YI, Csathy GS, Dorey F, Reiter RE, Aronson WJ: Preoperative p27 status is an independent predictor of prostate-specific antigen failure following radical prostatectomy. J Urol 2003;169:1325-1330.
13. Huang SP, Chou YH, Wayne Chang WS, Wu MT, Chen YY, Yu CC, Wu TT, Lee YH, Huang JK, Wu WJ, Huang CH: Association between vitamin d receptor polymorphisms and prostate cancer risk in a Taiwanese population. Cancer Lett 2004;207:69-77.
14. Huang SP, Wu WJ, Chang WS, Wu MT, Chen YY, Chen YJ, Yu CC, Wu TT, Lee YH, Huang JK, Huang CH: P53 codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev 2004;13:2217-2224.
15. Huang SP, Huang CY, Wu WJ, Pu YS, Chen J, Chen YY, Yu CC, Wu TT, Wang JS, Lee YH, Huang JK, Huang CH, Wu MT: Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy. Int J Cancer 2006;119:1902-1907.
16. Li G, Sturgis EM, Wang LE, Chamberlain RM, Spitz MR, El-Naggar AK, Hong WK, Wei Q: Association between the v109g polymorphism of the p27 gene and the risk and progression of oral squamous cell carcinoma. Clin Cancer Res 2004;10:3996-4002.
17. Kokontis JM, Hay N, Liao S: Progression of lncap prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 1998;12:941-953.
18. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKernion JB, Loda M, Reiter RE: Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998;159:941-945.
19. Kuczyk M, Machtens S, Hradil K, Schubach J, Christian W, Knuchel R, Hartmann J, Bokemeyer C, Jonas U, Serth J: Predictive value of decreased p27kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients. Br J Cancer 1999;81:1052-1058.
20. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW, Scher HI: Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 1999;91:1869-1876.
21. Freedland SJ, Sutter ME, Dorey F, Aronson WJ: Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003;61:365-369.